TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Stopping the use of laxatives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement (numeric rating scale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: wellbeing score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 25-hydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma parathyroid hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decannulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-mile run time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rating of perceived exertion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: FMD responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Hyperemia blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total tests ordered
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Follow-up visits scheduled
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Immunogenicity of NBP607
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of NBP607
Endpoint domain: Adverse events/effects
Primary endpoint: FRI Index score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antibacterial clinical efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TOS levels after phototherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidative stress index (OSI) after conventional phototherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean levels of PD (periodontal disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean value of FMPS (Full Mouth Plaque Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean value of FMBS (Full Mouth Bleeding Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T2 of the water resonance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day-14 mortality
Endpoint domain: Mortality/survival
Primary endpoint: Vasopressor dose decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating concentrations of IGF-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Circulating concentrations of IGFBP-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total number of asynchrony events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe asynchrony (asynchrony index > 10%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of typical drinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged analgesia duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total pain experienced over 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Top up requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of BV at 3 months postpartum
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of BV at 3 months postpartum
Endpoint domain: Adverse events/effects
Primary endpoint: HRC (Healing Rate of Canals)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FPS (Facial Pain Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: limitation of activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: worry about physical symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: shunt fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median best FSST time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to normotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients requiring additional doses of the study drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average hemoglobin level at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite cardiovascular end point
Endpoint domain: Mortality/survival
Primary endpoint: sit-to-stand test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatigue index of the right quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: physical domain of QOL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Need for mandibulectomy or radiation therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Survival at 1 hour (H1)
Endpoint domain: Mortality/survival
Primary endpoint: Survival at 24 hours (H24)
Endpoint domain: Mortality/survival
Primary endpoint: plasma erythropoietin (EPO) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sputum weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modification of Diet in Renal Disease estimated glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Long-term prognosis and cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Doppler flow parameters of the testicular artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Episodes of confirmed M. avium complex disease
Endpoint domain: Adverse events/effects
Primary endpoint: Bacterial pneumonia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation of study drug due to adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change from baseline in diastolic ABP at trough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change from baseline in systolic ABP at trough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of phonation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphologic information on brain MR imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contrast enhancement on brain MR imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: study agent-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Development of severe features of preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of TLR2 and TLR4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to dialysis/death
Endpoint domain: Mortality/survival
Primary endpoint: mean pain level at probe insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during biopsy punctures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of peripheral blood eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak Expiratory Flow (PEF) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 24-hour mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Depth of inflammation ≤ 2.8 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Micro-abscesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of eosinophils and neutrophils ≥ 150/mm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: patient perception of the deformity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 12-month transition rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPI pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGI-I global improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Serum sFAS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in PPG 2 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in FPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total seizure frequency reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Scores on the St. George's Respiratory Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity of DNA cytometry testing for cervical cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of cytologic testing for cervical cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adverse events reported after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment discontinuation due to TLADR
Endpoint domain: Adverse events/effects
Primary endpoint: Mean radiation dose per procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMD of leg flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMD of leg extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2max average increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 at VT average increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak power output increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Homeostasis model of assessment-insulin resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Homeostatic model assessment-beta cell function (HOMA-B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clitoral blood flow improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: GRISS scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: symptomatic relief of ocular dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement on tear stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin secretion percent change from baseline during the postprandial state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin secretion percent change from baseline during the fasting state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucagon area under the curve in the postprandial state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cumulative second cancer risk
Endpoint domain: Adverse events/effects
Primary endpoint: Mean scores for heat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean scores for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minor adverse clinical experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Change in epithelial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory block median onset times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete motor block within 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge and self-management improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of bronchitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Carrier rate of Hib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of patient-ventilator asynchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reducing anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reducing depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial excursions of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial oxidative stress (measured by nitrotyrosine, ox-LDL, and TRAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reducing mortality from advanced-stage ovarian cancer
Endpoint domain: Mortality/survival
Primary endpoint: patient-reported procedural pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disappearance of the bay sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Median stool frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: discretionary food intake maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: moderate to vigorous physical activity (MVPA) maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exclusion of atrial thrombi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of thromboembolic complications after CV
Endpoint domain: Adverse events/effects
Primary endpoint: clinically significant bronchoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Renal artery cross‐sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MCAvmean
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cerebrovascular outcomes
Primary endpoint: PCAvmean
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cerebrovascular outcomes
Primary endpoint: Achievement of HbA1c lower than 58 mmol/mol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cost difference between CSII and MDI
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to arrival at the hub
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to start study drug
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: clinical response to therapy at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Required dose of ephedrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0,∞) adjusted geometric mean ratio for midazolam plus tofacitinib to midazolam alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (C(max)) adjusted geometric mean ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate on first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of moderate to severe symptomatic hyperlactatemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of lactic acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mortality due to lactic acidosis and/or hemorrhagic pancreatitis
Endpoint domain: Mortality/survival
Primary endpoint: Systemic exposure to escitalopram (AUC0, infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of escitalopram (t(1/2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in overall IBDQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Normal or near-normal frequency of bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Satisfaction with personal life
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: binge drinking in girls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: binge drinking in boys
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful opioid use outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative deviation at distance and near
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates within 10(Δ) of orthophoria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of noninvasive breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Rate of valid test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate Apical Margin (PAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Three-year survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Survival among patients with Glasgow Coma Scale score less than 9
Endpoint domain: Mortality/survival
Primary endpoint: Re-admission rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean days of hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean score of the CBSE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional autonomy improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of hemoglobin S
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: arterial tortuosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: first cycle live birth rate
Endpoint domain: Mortality/survival
Primary endpoint: OHSS risks
Endpoint domain: Adverse events/effects
Primary endpoint: Likelihood of having a shunt placed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fewer symptoms (rigors and myalgias)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diminished peak cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Inhibition of PAF-induced platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Performance at laparoscopic salpingectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: need for further imaging
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: nasopharyngeal volume (NPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lesion conspicuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean weighted ADCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Normalization of elevated leukocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: skin moisture retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: erythema levels
Endpoint domain: Adverse events/effects
Primary endpoint: melanin levels
Endpoint domain: Adverse events/effects
Primary endpoint: 10-year cumulative relapse risk
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of P. aeruginosa infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total CF-CT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Cardiac Events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physical and emotional role functioning scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Missed work or required help at home
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: morning blood pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: caesarean delivery rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average correctness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to answer queries
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of vascular involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes